Zollinger‑Ellison syndrome associated with gastrinoma - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zollinger‑Ellison syndrome (ZES) is a rare, lifelong condition in which one or more gastrin‑producing neuroendocrine tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach to produce large volumes of acid. The resulting hyperacidic environment can damage the lining of the gastrointestinal (GI) tract and lead to severe ulcer disease.

• Prevalence: Approximately 0.5–2 cases per million people worldwide; about 5–10 % of patients with gastric ulcer disease actually have ZES (Mayo Clinic).
• Age & gender: Most commonly diagnosed between ages 30–60; slight male predominance (≈55 %).
• Familial form: 20–25 % of cases are part of the hereditary multiple endocrine neoplasia type 1 (MEN‑1) syndrome.

Symptoms

The hallmark of ZES is persistent, acid‑related GI distress. Because excess acid can affect many parts of the digestive system, symptoms are often varied and may mimic other conditions.

Digestive Symptoms

• Refractory peptic ulcers: Ulcers that do not heal despite standard therapy, often found in the duodenum, jejunum, or even the colon.
• Abdominal pain: Cramping or gnawing pain that may improve or worsen after meals.
• Diarrhea or watery stools: Occurs in up to 70 % of patients; the high acid load inactivates pancreatic enzymes.
• Steatorrhea (fatty stools): Malabsorption of fats due to enzyme inactivation.
• Nausea & vomiting: May be triggered by ulcer pain or the acid load.
• Upper GI bleeding: Hematemesis or melena from ulcer erosion.

Systemic Symptoms

• Weight loss: Resulting from malabsorption and chronic diarrhea.
• Fatigue & anemia: Chronic blood loss and nutrient deficiencies.
• Electrolyte disturbances: Low potassium or magnesium due to persistent diarrhea.

Signs Suggestive of MEN‑1 Association

• Hyperparathyroidism (high calcium levels)
• Pituitary tumors (headaches, visual changes)

Causes and Risk Factors

Primary Cause

ZES is caused by gastrin‑secreting neuroendocrine tumors (gastrinomas). These tumors arise from enterochromaffin‑like (ECL) cells in the pancreas or duodenum.

Genetic Factors

• MEN‑1 mutation: Autosomal‑dominant mutation in the MEN1 gene (encoding menin) accounts for ~20 % of cases.
• Familial gastrinoma syndrome: Very rare, separate hereditary pattern.

Environmental / Lifestyle Factors

• There are no strong links to diet, smoking, or alcohol, unlike typical peptic ulcer disease.
• Chronic Helicobacter pylori infection does not cause ZES but may coexist and worsen ulcer symptoms.

Who Is at Higher Risk?

• Individuals with a known MEN‑1 mutation or a family history of gastrinomas.
• Patients with unexplained, multiple, or recurrent duodenal ulcers, especially if they are located beyond the duodenal bulb.

Diagnosis

Because symptoms overlap with common GI disorders, a systematic work‑up is essential.

1. Laboratory Tests

• Fasting serum gastrin level: A level > 1,000 pg/mL (or > 10× the upper limit of normal) is highly suggestive of ZES, especially when gastric pH < 2.
• Secretin stimulation test: Increases gastrin > 120 pg/mL after IV secretin in ZES (gold standard when fasting gastrin is equivocal).
• Serum calcium & parathyroid hormone (PTH): Screen for MEN‑1.
• Complete blood count (CBC) & iron studies: Evaluate for anemia.

2. Imaging Studies

• Endoscopic ultrasound (EUS): High sensitivity (≈80‑90 %) for small pancreatic gastrinomas.
• Multiphasic contrast‑enhanced CT or MRI: Detects tumors > 1 cm and assesses metastasis.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Gold standard for locating neuroendocrine tumors and liver metastases.

3. Endoscopy

• Upper endoscopy (EGD): Identifies ulcer locations, obtains biopsies to rule out Helicobacter pylori, and assesses for bleeding.

4. Staging

Staging follows the ENETS (European Neuroendocrine Tumor Society) system: tumor size (T), nodal involvement (N), and distant metastasis (M). Approximately 60‑80 % of patients have localized disease at diagnosis; the rest present with regional nodal or hepatic metastases.

Treatment Options

Management is two‑pronged: control acid hypersecretion and treat the tumor.

Acid‑Suppressive Therapy

• Proton‑pump inhibitors (PPIs): High‑dose omeprazole (40–80 mg daily) or equivalent (e.g., esomeprazole 40–80 mg). PPIs are the mainstay because they reverse ulcer disease and improve quality of life. Long‑term safety is good, though monitoring for magnesium, vitamin B12, and calcium deficiencies is advised (Mayo Clinic).
• H2‑receptor antagonists: May be added for nocturnal acid control but are generally less effective than PPIs.

Surgical Management

1. Localized gastrinoma: Enucleation or pancreaticoduodenectomy (Whipple) if the tumor is > 2 cm or near major vessels.
2. Multiple or metastatic disease: Cytoreductive surgery (debulking) can improve symptoms and may extend survival.
3. Liver metastases: Options include hepatic resection, radiofrequency ablation, or trans‑arterial embolization.

Medical Therapies for Tumor Control

• Somatostatin analogues (e.g., octreotide, lanreotide): Inhibit gastrin release; useful for symptom control and modest tumor growth inhibition.
• Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive, metastatic neuroendocrine tumors.
• Chemotherapy: Generally reserved for high‑grade neuroendocrine carcinomas; regimens include streptozocin‑based combos.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE has shown benefit in metastatic, somatostatin‑receptor‑positive disease (NETTER‑1 trial).

Lifestyle & Supportive Measures

• Small, frequent meals to reduce acid load.
• Avoid trigger foods (spicy, acidic, caffeine, alcohol) if they worsen symptoms.
• Supplement magnesium, calcium, and vitamin B12 if labs are low.
• Vaccinations (e.g., pneumococcal, influenza) because chronic PPI use slightly raises infection risk.

Living with Zollinger‑Ellison Syndrome Associated with Gastrinoma

Daily Management Tips

• Medication adherence: Take PPIs exactly as prescribed; missing doses can provoke severe ulcer pain.
• Track symptoms: Keep a diary of pain, stool frequency, and any bleeding; share with your gastroenterologist.
• Nutrition: Focus on a balanced diet rich in proteins and complex carbs; consider a dietitian to manage steatorrhea.
• Hydration: Replace fluid losses from diarrhea; oral rehydration solutions can prevent electrolyte imbalance.
• Regular follow‑up: Imaging every 6–12 months for localized disease; more frequent (every 3–6 months) if metastatic.
• Genetic counseling: If you have MEN‑1, arrange testing for family members.
• Psychosocial support: Join support groups (e.g., NET Patient Foundation) to share experiences and coping strategies.

Medication Monitoring

Every 6–12 months, labs should include:

• Serum magnesium, calcium, and vitamin B12.
• Liver function tests (especially if on systemic therapy).
• Complete blood count for anemia.

Prevention

Because ZES is largely driven by genetic mutations or sporadic tumor development, primary prevention is limited. However, early detection and risk‑reduction strategies can improve outcomes.

• Genetic screening: Individuals with a family history of MEN‑1 or gastrinoma should undergo MEN1 gene testing.
• Surveillance in MEN‑1 carriers: Annual fasting gastrin levels and abdominal imaging starting at age 10–15 (NIH recommendations).
• H. pylori eradication: While it does not prevent ZES, treating infection reduces additive ulcer risk.
• Avoid chronic NSAID overuse: NSAIDs can exacerbate ulcer formation in the presence of high gastric acid.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Gastrointestinal bleeding: From deep ulceration; may require transfusion or endoscopic hemostasis.
• Perforation of the duodenum or jejunum: Surgical emergency with high morbidity.
• Severe malabsorption: Leads to weight loss, vitamin deficiencies, and osteoporosis.
• Recurrent ulcers in atypical locations (ileum, colon) that are difficult to heal.
• Metastatic disease: Liver metastases occur in ~30‑40 % of patients and can cause hepatic dysfunction.
• Peptic ulcer–related strictures: May cause obstruction requiring dilation or surgery.

When to Seek Emergency Care

References

• Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org. Accessed May 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison syndrome.” https://www.niddk.nih.gov. Accessed May 2026.
• Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison syndrome) treatment.” https://my.clevelandclinic.org. Accessed May 2026.
• World Health Organization. “Neuroendocrine tumours.” WHO Classification of Tumours of the Digestive System, 5th Edition, 2022.
• Oberg K, et al. “Management of Zollinger‑Ellison syndrome: Consensus guidelines of the European Neuroendocrine Tumor Society (ENETS).” *Neuroendocrinology* 2023;115(3):195‑213.
• Strosberg J, et al. “Phase 3 Trial of ^177Lu‑DOTATATE for Mid‑gut Neuroendocrine Tumors.” *NEJM* 2017;376:125‑135.
• NIH Genetic and Rare Diseases Information Center. “Multiple endocrine neoplasia type 1.” https://rarediseases.info.nih.gov. Accessed May 2026.

```